2:33
Gilead Sciences CEO John Martin, Ph.D., on HIV Treatment Innovation & Healthcare Reform
Gilead Sciences Chairman of the Board & CEO John Martin, Ph.D., discusses HIV treatmen...
published: 11 Nov 2009
Author: CHIinnovation
Gilead Sciences CEO John Martin, Ph.D., on HIV Treatment Innovation & Healthcare Reform
Gilead Sciences Chairman of the Board & CEO John Martin, Ph.D., discusses HIV treatment innovation and the the potential impact of healthcare reform.
2:00
The Next Big Thing In Biotech: Gilead Sciences
The Next Big Thing In Biotech: Gilead Sciences...
published: 24 Aug 2012
Author: TheStreetTV
The Next Big Thing In Biotech: Gilead Sciences
The Next Big Thing In Biotech: Gilead Sciences
3:31
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994...
published: 23 May 2012
Author: sunshinejen100
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
Dr. Michael Riordan Gilead Sciences founder, CEO Chairman interview 1994
1:35
Gilead Sciences (GILD) European CHMP Adopts Positive Opinion for Eviplera - CRWENewswire Stock Watch
Welcome to CRWENewswire, Stocks to watch. I am Christina Collins Human immunodeficiency vi...
published: 24 Sep 2011
Author: crwenewswire
Gilead Sciences (GILD) European CHMP Adopts Positive Opinion for Eviplera - CRWENewswire Stock Watch
Welcome to CRWENewswire, Stocks to watch. I am Christina Collins Human immunodeficiency virus (HIV) is a lentivirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Gilead Sciences Incorporated - symbol GILD - reported that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen for the Treatment of HIV-1 infection, Eviplera, combining Gilead's Truvada and Tibotec Pharmaceuticals' Edurant Gilead expects the European Commission to issue its decision on the marketing authorization for the Eviplera single-tablet regimen later this year. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Thank you for joining me and stay with us! For CRWE Newswire, Stocks to Watch, I'm Christina Collins ********************************* THIS ISNOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at www.crwenewswire <b>...</b>
2:52
Gilead Sciences Holds the Key to the Cure of Hepatitis C
www.change.org or goo.gl to sign petition. We need 100000 signatues by July 28! This is yo...
published: 01 Jul 2012
Author: texasrenegade1952
Gilead Sciences Holds the Key to the Cure of Hepatitis C
www.change.org or goo.gl to sign petition. We need 100000 signatues by July 28! This is your call to action! YOU CAN MAKE A DIFFERENCE! Gilead Sciences holds the key to the cure of the hepatitis C virus. This is an open letter imploring Gilead Sciences to do the right thing.
1:58
HIV treatment adds a third one-a-day pill
Gilead Sciences' one-pill-a-day HIV drug Quad is in the final phases of testing and co...
published: 06 Aug 2012
Author: NMANewsDirect
HIV treatment adds a third one-a-day pill
Gilead Sciences' one-pill-a-day HIV drug Quad is in the final phases of testing and could be approved by the FDA in August. If approved, Quad would become the third once-a-day pill to reach the market, after Atripla and Complera. The release of these drugs has vastly improved the lives of many HIV carriers who previously used so-called "cocktail" therapy, several pills taken several times a day, to manage their infections. Quad is a four-in-one pill that contains Emtricitabine (FTC), TDF, Elvitegravir (ETV) and Cobicistat. This animation demonstrates how FTC works to inhibit HIV RNA transcription.
2:51
Exclusive: HCV Cure - Open Letter to Gilead Sciences
www.change.org or goo.gl to sign petition. We need 100000 signatues by July 28! This is yo...
published: 22 Jun 2012
Author: texasrenegade1952
Exclusive: HCV Cure - Open Letter to Gilead Sciences
www.change.org or goo.gl to sign petition. We need 100000 signatues by July 28! This is your call to action! YOU CAN MAKE A DIFFERENCE! Gilead Sciences holds the key to the cure of the hepatitis C virus. This is an open letter imploring Gilead Sciences to do the right thing.
3:13
Buy Calls on Gilead Sciences
www.options-trading-education.com Buy Calls on Gilead Sciences Now that the world has its ...
published: 23 Jul 2012
Author: OptionsTips
Buy Calls on Gilead Sciences
www.options-trading-education.com Buy Calls on Gilead Sciences Now that the world has its first preventative drug for HIV, Truvada, is it time to buy calls on Gilead Sciences -- GILD, the folks who own the patent? Or is it too late to buy calls on Gilead Sciences because the market already reacted to the news of FDA approval? Remember that both fundamentals and market sentiment drive stock prices. We have yet to see if this $11000 a year drug will sell widely enough to make Gilead Sciences a profit. And we have yet to see how the market will react once this drug is in continual use. Gilead Sciences has been listed on NASDAQ for twenty years and for the first six it was a penny stock. The company specializes in the development of anti-viral treatments and currently has fourteen products on the market. Its focus has been on HIV, hepatitis B, and influenza. The stock's pre-recession high was around $56 and it regained the $50 range, coming up from $35 a share, early in 2012. Gilead Sciences only gapped up fifty cents on the news of FDA approval for the drug. Concerns are that it is so expensive that those most at risk will not be able to afford it and neither will government programs aimed at treating HIV in the same populations. Before deciding to jump in and buy calls on Gilead Sciences one may do well to consider how to trade stock options on this Gilead Sciences over time. When Will We Know How Profitable Truvada Is for Gilead Sciences? How many people will use Truvada <b>...</b>
7:35
Gilead Sciences (GILD) 2010
Gilead Sciences (GILD) 2010 annual results from operations....
published: 31 Aug 2011
Author: claudio170777
Gilead Sciences (GILD) 2010
Gilead Sciences (GILD) 2010 annual results from operations.
2:55
Pop Fiction @ Gilead Sciences
Aimee "The Rock Star" Lallana...
published: 22 Jun 2012
Author: Benny Villanueva
Pop Fiction @ Gilead Sciences
Aimee "The Rock Star" Lallana
2:30
Hepatitis C is Cured - We want the Cure Now
www.change.org or goo.gl Two companies - Gilead Sciences & Bristol-Myers Squibb Two dr...
published: 07 Aug 2012
Author: mdudley1951
Hepatitis C is Cured - We want the Cure Now
www.change.org or goo.gl Two companies - Gilead Sciences & Bristol-Myers Squibb Two drugs - GS-7977 + daclatasvir One Cure - For Hepatitis C (without ribavirin and/or interferon) There is a CURE for Hepatitis C and Gilead Sciences HOLDS the KEY...SIGN petition to make them OPEN the DOOR...NOW!
1:21
Stock Market Earnings GILD Gilead Sciences Report
www.StockMarketFunding.com Stock Market Earnings GILD Gilead Sciences Report. Live stock m...
published: 25 Jan 2011
Author: StockMarketFunding
Stock Market Earnings GILD Gilead Sciences Report
www.StockMarketFunding.com Stock Market Earnings GILD Gilead Sciences Report. Live stock market trading analysis on GILD After Hours Trading Results. Altera Corporation (Nasdaq - News) today announced fourth quarter sales of $555.4 million, up 5 percent from the third quarter of 2010 and up 52 percent from the fourth quarter of 2009. New product sales increased 26 percent sequentially. Fourth quarter net income was $231.6 million, $0.72 per diluted share, compared with net income of $217.5 million, $0.69 per diluted share, in the third quarter of 2010 and $103.0 million, $0.34 per diluted share, in the fourth quarter of 2009. Cash flow from operating activities in 2010 was $856.7 million. Altera ended the quarter with $2.8 billion in cash and short-term investments. Altera's board of directors has declared a quarterly cash dividend of $0.06 per share payable on March 1, 2011 to stockholders of record on February 10, 2011. "The fourth quarter delivered a positive note to end a remarkable sales growth year. Our sales were up 64 percent in 2010, significantly outpacing most companies in the semiconductor industry. In the fourth quarter, new products continued to be growth drivers as we saw substantial sales gains from our 65-nm and 40-nm FPGAs," said John Daane, president, chief executive officer, and chairman of the board. "During the fourth quarter we taped out our first 28-nm FPGAs. We believe Altera's unique features and performance will extend our technology leadership <b>...</b>
1:08
Gilead Sciences Entered Into A License Agreement With Tibotec Pharmaceuticals
Gilead Sciences (NASDAQ:GILD) announced that it has entered into a license agreement with ...
published: 28 Jun 2011
Author: FinancialNewsOnline
Gilead Sciences Entered Into A License Agreement With Tibotec Pharmaceuticals
Gilead Sciences (NASDAQ:GILD) announced that it has entered into a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a new fixed-dose antiretroviral combination product containing the company's cobicistat and Tibotec's protease inhibitor Prezista. Norbert W. Bischofberger, PhD, Gilead's Executive Vice President and CFO, "Cobicistat's formulation and clinical profile provides us with the flexibility to co-formulate and develop new combination products, including the potential to co-formulate with protease inhibitors such as Prezista. This agreement represents another important step forward in our commitment to developing simplified treatment regimens that can help address the individual needs of people living with HIV." Gilead Sciences has a potential upside of 12.3% based on a current price of $40.89 and an average consensus analyst price target of $45.94.
1:17
Shares of Gilead Sciences Sink on Concerns Over Pipeline, Price Target Lowered to $38 (GILD)
July 16, 2010-- Shares of Gilead Sciences, Inc. (NASDAQ:GILD) took a hit earlier Friday, f...
published: 16 Jul 2010
Author: TradeTheTrend
Shares of Gilead Sciences Sink on Concerns Over Pipeline, Price Target Lowered to $38 (GILD)
July 16, 2010-- Shares of Gilead Sciences, Inc. (NASDAQ:GILD) took a hit earlier Friday, falling 8% to $32.04, reports MarketWatch, pushing the research-based biopharmaceutical company into the lead as a major S&P 500 decliner for the day. Jefferies & Co. lowered the firm's price target from $48 to $38, citing concerns over Gilead's pipeline and rumored competition for its HIV combination therapies.SmarTrend alerted subscribers to take profits in Gilead Sciences on March 26, 2010 at $45.66; since then, the stock fell 29.7%. We are now watching for any positive developments that could result in a new uptrend signal. Gilead Sciences is currently below its 50-day moving average (MA) of $36.07 and below its 200-day MA of $43.20. In the last five trading sessions, the 50-day MA has fallen 1.36%, while the 200-day MA has slid 0.66%. Shares of the company continue to trade down 8.02% Friday afternoon at $32.10.
Youtube results:
1:48
Do You Have Hepatitis C?
www.change.org or goo.gl A new treatment for the Hepatitis C Virus with a 100% cure rate f...
published: 21 Jul 2012
Author: texasrenegade1952
Do You Have Hepatitis C?
www.change.org or goo.gl A new treatment for the Hepatitis C Virus with a 100% cure rate for genotype 1 and a 91% cure rate for genotype 2/3 has been found. But, It seems that the love of money is clouding the vision of Gilead Sciences.
0:24
Gilead Protest Video (8/3/11)
Gilead "Die-In" Protest at Foster City, CA headquarters of Gilead Sciences Inc. ...
published: 03 Aug 2011
Author: aidshealth
Gilead Protest Video (8/3/11)
Gilead "Die-In" Protest at Foster City, CA headquarters of Gilead Sciences Inc. to protest the company's pricing of its HIV/AIDS medications.
8:26
Mid-Day Update: A Look At Biotech and Pharma
Evan Lazarus, Mentor in the Active Trading room, pulls up the charts of the Apple (NASDAQ:...
published: 18 Sep 2012
Author: t3live
Mid-Day Update: A Look At Biotech and Pharma
Evan Lazarus, Mentor in the Active Trading room, pulls up the charts of the Apple (NASDAQ:AAPL), and then dives into biotech: Jazz pharmaceuticals (NASDAQ:JAZZ), Celgene (NASDAQ:CELG), Onyx Pharmaceuticals (NASDAQ:ONXX), and Gilead Sciences (NASDAQ:GILD).
0:47
Gilead Sciences Topped Q2 Estimates, Top Line Up 11%
Gilead Sciences (NASDAQ:GILD)reported Q2 EPS of $1.00, ahead of consensus estimates of $0....
published: 26 Jul 2011
Author: FinancialNewsOnline
Gilead Sciences Topped Q2 Estimates, Top Line Up 11%
Gilead Sciences (NASDAQ:GILD)reported Q2 EPS of $1.00, ahead of consensus estimates of $0.99 per share. Revenues for the quarter rose 11% year-over-year to $2.14 billion, topping consensus estimates of $2.07 billion. Product sales rose 13% to $2.04 billion during the quarter. The increase in sales was driven primarily by the company's antiviral franchise. Gilead Sciences has a potential upside of 10.8% based on a current price of $42.16 and an average consensus analyst price target of $46.69.